Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114806) titled 'Application of Eculizumab in the Prevention and Treatment of Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation with High Titers of Blood Group Antibodies: A Single-Center, Open-Label, Single-Arm Study' on Dec. 17, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Guangdong Provincial People's Hospital
Condition:
Rejection
Intervention:
Experimental Group:1. The recipient of the participant received a single dose of Eculizumab one day before the transplantation surgery (900 mg for weight >=60kg). For those with a body weight of less than 60kg, 600 mg shoul...